NP680262.RABg 8k2CA-VMrfyKe4 oDKHWqRVwyFuaiayXhVb hTeY
has assertion: NP680262.RABg 8k2CA-VMrfyKe4 oDKHWqRVwyFuaiayXhVb hTeY130 assertion
has provenance: NP680262.RABg 8k2CA-VMrfyKe4 oDKHWqRVwyFuaiayXhVb hTeY130 provenance
has publication info: NP680262.RABg 8k2CA-VMrfyKe4 oDKHWqRVwyFuaiayXhVb hTeY130 publicationInfo
type: Nanopublication
created: 2016-05-13T12:46:53+02:00
rights: http://opendatacommons.org/licenses/odbl/1.0/
rights holder: IBIGroup
subject: SIO_000983
used data: disgenetv3.0rdf
authored by: http://orcid.org/0000-0001-5999-6269
authored by: http://orcid.org/0000-0002-7534-7661
authored by: 0000-0002-9383-528X
authored by: http://orcid.org/0000-0003-0169-8159
authored by: http://orcid.org/0000-0003-1244-7654
created by: http://orcid.org/0000-0003-0169-8159
version: v4.0.0.0

NP680262.RABg 8k2CA-VMrfyKe4 oDKHWqRVwyFuaiayXhVb hTeY130 assertion
type: Assertion
description: [Sixty-four patients including 41 positive for hepatitis B e antigen (HBeAg) were assigned to receive either (1) a combination of interferon-alpha (6 million units daily for 2 weeks, then three times weekly) plus lamivudine (100 mg daily) for 24 weeks followed by lamivudine alone for 28 weeks (n = 30) or (2) 52-week lamivudine monotherapy (n = 34).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine.
evidence: DisGeNET evidence - LITERATURE
SIO_000772: http://identifiers.org/pubmed/18600390
was generated by: ECO_0000203

befree-2016
imported on: 2016-02-19

DisGeNET evidence - LITERATURE
type: ECO_0000212
comment: Gene-disease associations inferred from text-mining the literature.

disgenetv3.0rdf
version: v4.0.0